Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oteracil→

Oteracil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
937-13-3
Molecular formula
C4H3N3O4
Molecular weight
157.08 g/mol
Drug class
Orotate phosphoribosyltransferase (OPRT) inhibitorfluoropyrimidine-modulating component
Mechanism of action
Oteracil potassium preferentially localises in gastrointestinal tissues and inhibits orotate phosphoribosyltransferase, reducing conversion of 5-fluorouracil to active metabolites in the gut and thereby reducing gastrointestinal toxicity when used in the tegafur/gimeracil/oteracil (S-1) combination.
Indications / reported uses
  • Used only as a component of the fixed-dose tegafur/gimeracil/oteracil combination (S-1/Teysuno) for selected solid tumours; oteracil alone is not a stand-alone antineoplastic treatment.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-gimeracil-oteracil-potassium · https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno · https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oteracil Environmental Risk Assessment (ERA) (the Oteracil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.